Immunologic messenger molecules: Cytokines, interferons, and chemokines

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Commins, Scott P ^a   Borish, Larry ^a   Steinke, John W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

antigen presenting cell; chemokine; Cytokine; interferon; T lymphocyte

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 25; INTERLEUKIN 28; INTERLEUKIN 29; INTERLEUKIN 3; INTERLEUKIN 31; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 9; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ALLERGY; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; EOSINOPHILIA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL COMMUNICATION; CELL MOVEMENT; CHEMOKINES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; INTERFERONS; T-LYMPHOCYTES;

EID: 76749109317     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.07.008     Document Type: Article

References (172)

1. Beutler B., and Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 7 (1989) 625-655
2. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., and Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63 (1990) 251-258
3. Tartaglia L.A., and Goeddel D.V. Two TNF receptors. Immunol Today 13 (1992) 151-153
4. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
5. Dinarello C.A., and Wolff S.M. The role of interleukin-1 in disease. N Engl J Med 328 (1993) 106-113
6. Sims J.E., Gayle M.A., Slack J.L., Alderson M.R., Bird T.A., Giri J.G., et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A 90 (1993) 6155-6159
7. Arend W.P. Interleukin-1 receptor antagonist. Adv Immunol 54 (1993) 167-227
8. Cerretti D.P., Kozlosky C.J., Mosley B., Nelson N., Van Ness K., Greenstreet T.A., et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 256 (1992) 97-100
9. Akira S., Taga T., and Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54 (1993) 1-78
10. Muller-Newen G., Kuster A., Hemmann U., Keul R., Horsten U., Martens A., et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161 (1998) 6347-6355
11. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
12. Brunda M.J. Interleukin-12. J Leukoc Biol 55 (1994) 280-288
13. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
14. Dinarello C.A. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 11 (2000) 483-486
15. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264 (1994) 965-968
16. Larousserie F., Bardel E., Pflanz S., Arnulf B., Lome-Maldonado C., Hermine O., et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 166 (2005) 1217-1228
17. Pflanz S., Hibbert L., Mattson J., Rosales R., Vaisberg E., Bazan J.F., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172 (2004) 2225-2231
18. Kim S.H., Han S.Y., Azam T., Yoon D.Y., and Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
19. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Walsh M., Park J.S., et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A 102 (2005) 16309-16314
20. Minshall E., Chakir J., Laviolette M., Molet S., Zhu Z., Olivenstein R., et al. IL-11 expression is increased in severe asthma: association with epithelial cells and eosinophils. J Allergy Clin Immunol 105 (2000) 232-238
21. Tang W., Geba G.P., Zheng T., Ray P., Homer R.J., Kuhn III C., et al. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J Clin Invest 98 (1996) 2845-2853
22. Adolf G.R. Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) omega 1: evidence that IFN-omega 1 is a component of human leukocyte IFN. Virology 175 (1990) 410-417
23. Adolf G.R., Maurer-Fogy I., Kalsner I., and Cantell K. Purification and characterization of natural human interferon omega 1. Two alternative cleavage sites for the signal peptidase. J Biol Chem 265 (1990) 9290-9295
24. Flores I., Mariano T.M., and Pestka S. Human interferon omega binds to the alpha/beta receptor. J Biol Chem 266 (1991) 19875-19877
25. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
26. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 (2003) 69-77
27. Mennechet F.J., and Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107 (2006) 4417-4423
28. Konforte D., Simard N., and Paige C.J. IL-21: an executor of B cell fate. J Immunol 182 (2009) 1781-1787
29. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
30. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
31. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 (2001) 2108-2111
32. Castigli E., Wilson S.A., Garibyan L., Rachid R., Bonilla F., Schneider L., et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37 (2005) 829-834
33. Salzer U., Chapel H.M., Webster A.D., Pan-Hammarstrom Q., Schmitt-Graeff A., Schlesier M., et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37 (2005) 820-828
34. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
35. Thornton A.M., Donovan E.E., Piccirillo C.A., and Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4 + CD25 + T cell suppressor function. J Immunol 172 (2004) 6519-6523
36. Farrar M.A., and Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11 (1993) 571-611
37. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335 (1996) 1941-1949
38. Bach E.A., Aguet M., and Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15 (1997) 563-591
39. Cruikshank W.W., Center D.M., Nisar N., Wu M., Natke B., Theodore A.C., et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci U S A 91 (1994) 5109-5113
40. Wilson K.C., Center D.M., and Cruikshank W.W. The effect of interleukin-16 and its precursor on T lymphocyte activation and growth. Growth Factors 22 (2004) 97-104
41. Kawaguchi M., Adachi M., Oda N., Kokubu F., and Huang S.K. IL-17 cytokine family. J Allergy Clin Immunol 114 (2004) 1265-1274
42. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Page N., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 108 (2001) 430-438
43. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30 (2009) 108-119
44. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452 (2008) 773-776
45. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205 (2008) 1551-1557
46. Minegishi Y., Saito M., Nagasawa M., Takada H., Hara T., Tsuchiya S., et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 206 (2009) 1291-1301
47. Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320 (2008) 807-811
48. Paul W.E., and Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 5 (1987) 429-459
49. Coffman R.L., Ohara J., Bond M.W., Carty J., Zlotnik A., and Paul W.E. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 136 (1986) 4538-4541
50. Romagnani S. Regulation and deregulation of human IgE synthesis. Immunol Today 11 (1990) 316-321
51. Vella A., Teague T.K., Ihle J., Kappler J., and Marrack P. Interleukin 4 (IL-4) or IL-7 prevents death of resting T cells: Stat-6 is probably not required for the effect of IL-4. J Exp Med 186 (1997) 325-330
52. Enelow R., Baramki D.F., and Borish L.C. Inhibition of effector T lymphocytes mediated through antagonism of IL-4. J Allergy Clin Immunol 113 (2004) 560-562
53. Schleimer R.P., Sterbinsky S.A., Kaiser J., Bickel C.A., Klunk D.A., Tomioka K., et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 148 (1992) 1086-1092
54. Hsieh F.H., Lam B.K., Penrose J.F., Austen K.F., and Boyce J.A. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 193 (2001) 123-133
55. Izuhara K., and Shirakawa T. Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 3 (1999) 3-10
56. Steinke J.W., Negri J., Enelow R., Baramki D.F., and Borish L. Proinflammatory effects of IL-4 antagonism. J Allergy Clin Immunol 118 (2006) 756-758
57. Zurawski G., and de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15 (1994) 19-26
58. Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161 (1998) 2317-2324
59. Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103 (1999) 779-788
60. Clutterbuck E.J., Hirst E.M., and Sanderson C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73 (1989) 1504-1512
61. Mould A.W., Ramsay A.J., Matthaei K.I., Young I.G., Rothenberg M.E., and Foster P.S. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol 164 (2000) 2142-2150
62. Rothenberg M.E., Petersen J., Stevens R.L., Silberstein D.S., McKenzie D.T., Austen K.F., et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 143 (1989) 2311-2316
63. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009) 973-984
64. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009) 985-993
65. Kitamura T., Sato N., Arai K., and Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 66 (1991) 1165-1174
66. Rothenberg M.E., Owen Jr. W.F., Silberstein D.S., Woods J., Soberman R.J., Austen K.F., et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 81 (1988) 1986-1992
67. Owen Jr. W.F., Rothenberg M.E., Silberstein D.S., Gasson J.C., Stevens R.L., Austen K.F., et al. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med 166 (1987) 129-141
68. Ochs M., Knudsen L., Allen L., Stumbaugh A., Levitt S., Nyengaard J.R., et al. GM-CSF mediates alveolar epithelial type II cell changes, but not emphysema-like pathology, in SP-D-deficient mice. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1333-L1341
69. Guth A.M., Janssen W.J., Bosio C.M., Crouch E.C., Henson P.M., and Dow S.W. Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 296 (2009) L936-L946
70. Anderson D.M., Lyman S.D., Baird A., Wignall J.M., Eisenman J., Rauch C., et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63 (1990) 235-243
71. Matsuda H., Kannan Y., Ushio H., Kiso Y., Kanemoto T., Suzuki H., et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 174 (1991) 7-14
72. Yanagida M., Fukamachi H., Ohgami K., Kuwaki T., Ishii H., Uzumaki H., et al. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86 (1995) 3705-3714
73. Tsuji K., Koike K., Komiyama A., Miyajima A., Arai K., and Nakahata T. Synergistic action of interleukin-10 (IL-10) with IL-3, IL-4 and stem cell factor on colony formation from murine mast cells in culture. Int J Hematol 61 (1995) 51-60
74. Godfraind C., Louahed J., Faulkner H., Vink A., Warnier G., Grencis R., et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 160 (1998) 3989-3996
75. Gebhardt T., Sellge G., Lorentz A., Raab R., Manns M.P., and Bischoff S.C. Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptor-dependent mediator release. Eur J Immunol 32 (2002) 2308-2316
76. Hultner L., Druez C., Moeller J., Uyttenhove C., Schmitt E., Rude E., et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 20 (1990) 1413-1416
77. Veldhoen M., Uyttenhove C., van Snick J., Helmby H., Westendorf A., Buer J., et al. Transforming growth factor-beta "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9 (2008) 1341-1346
78. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., et al. IL-4 inhibits TGF-beta-induced Foxp3 + T cells and, together with TGF-beta, generates IL-9 + IL-10 + Foxp3(-) effector T cells. Nat Immunol 9 (2008) 1347-1355
79. Fort M.M., Cheung J., Yen D., Li J., Zurawski S.M., Lo S., et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15 (2001) 985-995
80. Dillon S.R., Sprecher C., Hammond A., Bilsborough J., Rosenfeld-Franklin M., Presnell S.R., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5 (2004) 752-760
81. Neis M.M., Peters B., Dreuw A., Wenzel J., Bieber T., Mauch C., et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 118 (2006) 930-937
82. Sonkoly E., Muller A., Lauerma A.I., Pivarcsi A., Soto H., Kemeny L., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117 (2006) 411-417
83. Sporn M.B., and Roberts A.B. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 119 (1992) 1017-1021
84. Chen W., Frank M.E., Jin W., and Wahl S.M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14 (2001) 715-725
85. Sonoda E., Matsumoto R., Hitoshi Y., Ishii T., Sugimoto M., Araki S., et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 170 (1989) 1415-1420
86. Kay A.B., Phipps S., and Robinson D.S. A role for eosinophils in airway remodelling in asthma. Trends Immunol 25 (2004) 477-482
87. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., and Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150 (1993) 353-360
88. Ding L., Linsley P.S., Huang L.Y., Germain R.N., and Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151 (1993) 1224-1234
89. Taylor A., Akdis M., Joss A., Akkoc T., Wenig R., Colonna M., et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 120 (2007) 76-83
90. Borish L., Aarons A., Rumbyrt J., Cvietusa P., Negri J., and Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97 (1996) 1288-1296
91. Conti P., Kempuraj D., Frydas S., Kandere K., Boucher W., Letourneau R., et al. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett 88 (2003) 171-174
92. Liao S.C., Cheng Y.C., Wang Y.C., Wang C.W., Yang S.M., Yu C.K., et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 173 (2004) 6712-6718
93. Blumberg H., Conklin D., Xu W.F., Grossmann A., Brender T., Carollo S., et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104 (2001) 9-19
94. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., and Sabat R. IL-22 increases the innate immunity of tissues. Immunity 21 (2004) 241-254
95. Wolk K., Witte E., Hoffmann U., Doecke W.D., Endesfelder S., Asadullah K., et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 178 (2007) 5973-5981
96. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 52 (2005) 1037-1046
97. Whittington H.A., Armstrong L., Uppington K.M., and Millar A.B. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 31 (2004) 220-226
98. Mumm J.B., Ekmekcioglu S., Poindexter N.J., Chada S., and Grimm E.A. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res 26 (2006) 877-886
99. Zheng M., Bocangel D., Doneske B., Mhashilkar A., Ramesh R., Hunt K.K., et al. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother 56 (2007) 205-215
100. Hor S., Pirzer H., Dumoutier L., Bauer F., Wittmann S., Sticht H., et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 279 (2004) 33343-33351
101. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37 (2007) 3021-3029
102. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007) 566-569
103. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
104. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177 (1993) 1199-1204
105. Villarino A.V., Huang E., and Hunter C.A. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 173 (2004) 715-720
106. Seder R.A., Paul W.E., and Davis M.M. Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4 + T cells from T cell receptor transgenic mice. J Exp Med 176 (1992) 1091-1098
107. Bilenki L., Yang J., Fan Y., Wang S., and Yang X. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production. Eur J Immunol 34 (2004) 345-354
108. Akbari O., Faul J.L., Hoyte E.G., Berry G.J., Wahlstrom J., Kronenberg M., et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 354 (2006) 1117-1129
109. Gallagher G., Eskdale J., Jordan W., Peat J., Campbell J., Boniotto M., et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 4 (2004) 615-626
110. Tamachi T., Maezawa Y., Ikeda K., Kagami S., Hatano M., Seto Y., et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol 118 (2006) 606-614
111. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
112. Coyle A.J., Lloyd C., Tian J., Nguyen T., Erikkson C., Wang L., et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 190 (1999) 895-902
113. Xu D., Chan W.L., Leung B.P., Huang F., Wheeler R., Piedrafita D., et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187 (1998) 787-794
114. Lohning M., Stroehmann A., Coyle A.J., Grogan J.L., Lin S., Gutierrez-Ramos J.C., et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 95 (1998) 6930-6935
115. Wang Y.H., Ito T., Homey B., Watanabe N., Martin R., Barnes C.J., et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 24 (2006) 827-838
116. Al-Shami A., Spolski R., Kelly J., Keane-Myers A., and Leonard W.J. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 202 (2005) 829-839
117. Zhou B., Comeau M.R., De Smedt T., Liggitt H.D., Dahl M.E., Lewis D.B., et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 6 (2005) 1047-1053
118. Yoo J., Omori M., Gyarmati D., Zhou B., Aye T., Brewer A., et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202 (2005) 541-549
119. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3 (2002) 673-680
120. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6 (2006) 329-333
121. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
122. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
123. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
124. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357 (2007) 1608-1619
125. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 (2007) 1058-1062
126. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000) 455-458
127. Akdis C.A., Blesken T., Akdis M., Wuthrich B., and Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 102 (1998) 98-106
128. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10 + CD4 + CD25 + T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 (2003) 1255-1261
129. Darnell Jr. J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
130. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., Thierfelder W.E., Kreider B., et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 19 (1994) 222-227
131. Ghislain J.J., Wong T., Nguyen M., and Fish E.N. The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. J Interferon Cytokine Res 21 (2001) 379-388
132. Dumoutier L., Lejeune D., Hor S., Fickenscher H., and Renauld J.C. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 370 (2003) 391-396
133. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., and Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279 (2004) 32269-32274
134. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 380 (1996) 627-630
135. Losman J.A., Chen X.P., Hilton D., and Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 162 (1999) 3770-3774
136. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2 (2001) 123-128
137. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
138. Kelner G.S., Kennedy J., Bacon K.B., Kleyensteuber S., Largaespada D.A., Jenkins N.A., et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266 (1994) 1395-1399
139. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
140. Charo I.F., Myers S.J., Herman A., Franci C., Connolly A.J., and Coughlin S.R. Molecular cloning and functional expression of two monocyte chemoattractant protein-1 receptors reveals alternative splicing of the carboxy-terminal tails. Proc Natl Acad Sci U S A 91 (1994) 2752-2756
141. Ponath D.P., Qin S., Post T.W., Wang J., Wu L., Gerard N.P., et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183 (1996) 2437-2448
142. Daugherty B.L., Siciliano S.J., DeMartino J.A., Malkowitz L., Sirotina A., and Springer M.S. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 183 (1996) 2349-2354
143. Isik N., Hereld D., and Jin T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS ONE 3 (2008) e3424
144. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2 (2001) 129-134
145. Ma Y.C., Huang J., Ali S., Lowry W., and Huang X.Y. Src tyrosine kinase is a novel direct effector of G proteins. Cell 102 (2000) 635-646
146. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Annu Rev Immunol 15 (1997) 675-705
147. Li Z., Jiang H., Xie W., Zhang Z., Smrcka A., and Wu D. Roles of PLC-b2 and -b3 and PI3Kg in chemoattractant-mediated signal transduction. Science 287 (2000) 1046-1049
148. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S., and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI3-kinase γ. Science 275 (1997) 394-397
149. Balakin K.V., Ivanenkov Y.A., Tkachenko S.E., Kiselyov A.S., and Ivachtchenko A.V. Regulators of chemokine receptor activity as promising anticancer therapeutics. Curr Cancer Drug Targets 8 (2008) 299-340
150. Pruenster M., Muddle L., Bombosi P., Dimitrova S., Zsak M., Middleton J., et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 10 (2009) 101-108
151. Zarbock A., and Ley K. Neutrophil adhesion and activation under flow. Microcirculation 16 (2009) 31-42
152. Constantin G., Majeed M., Giagulli C., Piccio L., Kim J.Y., Butcher E.C., et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13 (2000) 759-769
153. Luther S.A., and Cyster J.G. Chemokines as regulators of T cell differentiation. Nat Immunol 2 (2001) 102-107
154. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2 (2001) 95-101
155. Breitfeld D., Ohl L., Kremmer E., Ellwart J., Sallusto F., Lipp M., et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 192 (2000) 1545-1552
156. Schaerli P., Willimann K., Lang A.B., Lipp M., Loetscher P., and Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 192 (2000) 1553-1562
157. von Vietinghoff S., and Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol 181 (2008) 5183-5188
158. Ying S., Merg Q., Zeibecoglou K., Robinson D.S., Macfarlane A., Humbert M., et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 163 (1999) 6321-6329
159. Miotto D., Christodoulopoulos P., Olivenstein R., Taha R., Cameron L., Tsicopoulos A., et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol 107 (2001) 664-670
160. Medoff B.D., Sauty A., Tager A.M., Maclean J.A., Smith R.N., Mathew A., et al. IFN-γ-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol 168 (2002) 5278-5286
161. Gonzalo J.A., Lloyd C.M., Peled A., Delaney T., Coyle A.J., and Gutierrez-Ramos J.C. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1a in the inflammatory component of allergic airway disease. J Immunol 165 (2000) 499-508
162. Gerard C., and Rollins B.J. Chemokines and disease. Nat Immunol 2 (2001) 108-115
163. Venge J., Lampinen M., Hakansson L., Rak S., and Venge P. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J Allergy Clin Immunol 97 (1996) 1110-1115
164. Meurer R., Van Riper G., Feeney W., Cunningham P., Hora D., Springer M.S., et al. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8. J Exp Med 178 (1993) 1913-1921
165. Terada N., Nomura T., Kim W.J., Otsuka Y., Takahashi R., Kishi H., et al. Expression of C-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clin Exp Allergy 31 (2001) 1923-1931
166. Hartl D., Latzin P., Zissel G., Krane M., Krauss-Etschmann S., and Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 173 (2006) 1370-1376
167. Oppenheim J.J., Zachariae C.O., Mukaida N., and Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9 (1991) 617-648
168. Horuk R. The interleukin-8-receptor family: from chemokines to malaria. Immunol Today 15 (1994) 169-174
169. Leonard E.J., and Yoshimura T. Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). Am J Respir Crit Care Med 2 (1990) 479-486
170. Fulkerson P.C., Zimmermann N., Hassman L.M., Finkelman F.D., and Rothenberg M.E. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J Immunol 173 (2004) 7565-7574
171. Reefer A.J., Satinover S.M., Solga M.D., Lannigan J.A., Nguyen J.T., Wilson B.B., et al. Analysis of CD25hiCD4+ "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population. J Allergy Clin Immunol 121 (2008) 415-422 e3
172. Nguyen K.D., Fohner A., Booker J.D., Dong C., Krensky A.M., and Nadeau K.C. XCL1 enhances regulatory activities of CD4 + CD25(high) CD127(low/-) T cells in human allergic asthma. J Immunol 181 (2008) 5386-5395